טוען...
Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?
The availability of disease-modifying drugs for the management of autosomal dominant polycystic kidney disease (ADPKD) has accelerated the need to accurately predict renal prognosis and/or treatment response in this condition. Arginine vasopressin (AVP) is a critical determinant of postnatal kidney...
שמור ב:
| הוצא לאור ב: | World J Nephrol |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Baishideng Publishing Group Inc
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5838414/ https://ncbi.nlm.nih.gov/pubmed/29527508 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5527/wjn.v7.i2.51 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|